Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Arezzo, 18 dicembre 2025 – È una delle artiste più versatili e amate dello spettacolo italiano: ballerina, conduttrice, attrice e speaker radiofonica. Nata a Martina Franca, dopo anni di studio di ...

Moderna (MRNA) closed the most recent trading day at $32.29, moving -7.48% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.46%. Elsewhere, the Dow ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once touted as a future blockbuster – after it failed the Phase 3 CMVictory trial ...

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. This stock is a ...

Arezzo, 30 dicembre 2025 – “Un 2025 davvero incredibile” così Roberto Scortecci, direttore artistico de La Maison della Danza. “A marzo abbiamo incontrato Little Phil, uno dei più grandi talenti ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups could help fill the void after the Trump administration slashed federal ...

Dec 18 (Reuters) - Moderna (MRNA.O), opens new tab will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S.

Moderna has rallied ~23%, but I maintain a 'Sell' and 'market underperform' rating due to deteriorating fundamentals. MRNA’s recent rally is driven by improved liquidity, cost discipline, and a $1.5 ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups could help fill the void after the Trump administration slashed federal ...

Vaccine stocks remain lucrative, with ongoing revenue from both COVID-19 and other vaccines. Before investing, assess a company's market products, regulatory status, and potential issues. Research ...